Reduced Nasal Nitric Oxide Production in Cystic Fibrosis Patients with Elevated Systemic Inflammation Markers

R. Michl, Julia Hentschel, Christiane Fischer, James F. Beck, Jochen G. MainzPLoS 2013 · DOI

Abstract

Given that NO in the paranasal sinuses is part of the first-line defence mechanism against pathogens, our finding of reduced nasal NO in CF patients with elevated systemic inflammatory markers indicates impaired upper airway defence. This may facilitate further pathogen acquisition in the sinonasal area, with consequences for lung colonisation and the overall outcome in CF.

Introduction

In Cystic Fibrosis (CF), the upper airways' primary chemical defense—nitric oxide (NO)—appears to fail just when it’s needed most. CF is characterized by chronic airway infections, typically starting in the upper respiratory tract (the nose and sinuses) before migrating to the lungs. Nitric oxide (NO) is a crucial part of our innate immune system; it acts as a vasodilator and a potent antimicrobial agent. While NO levels usually skyrocket during inflammation in diseases like asthma, the story in CF is complex. This study investigates how NO levels in both the upper and lower airways correlate with blood-based inflammation markers, clinical lung function, and specific pathogens.

Methods

The researchers conducted a cross-sectional study of 57 CF patients (ages 5–73) at Jena University Hospital. Key techniques included:

  • NO Measurement: Using an electrochemical analyzer to measure both nasal NO and exhaled bronchial NO.
  • Microbiology: Collecting sputum and nasal lavage samples to identify pathogen colonization in both the upper and lower airways.
  • Laboratory Work: Measuring systemic inflammation via C-reactive protein (CRP), leucocyte (white blood cell) counts, fibrinogen, and total IgG.
  • Statistical Modeling: Beyond simple correlations, the team used multivariate linear regression to account for factors like age, lung function (FEV1), and antibiotic use.

Key Results and Insights

A significant correlation was observed between nasal and bronchial NO levels (rho = 0.48). This supports the "united airways" theory, suggesting that physiological conditions in the sinuses are strong indicators of lower airway status.

Correlation between nasal and bronchial NO levels showing a positive relationship (rho = 0.48).

The Sinonasal Defense Gap

The most striking finding is the inverse correlation between systemic inflammation and nasal NO. As CRP (rho = -0.28, p = 0.04) and leucocyte counts (rho = -0.41, p = 0.003) increase, nasal NO levels decrease. This suggests that the "first-line defense" in the sinuses is impaired during systemic flares, contrary to the typical immune response seen in other respiratory diseases.

The Azithromycin Paradox and Therapy Effects

Patients receiving azithromycin (AZM), a common anti-inflammatory antibiotic in CF, showed significantly lower bronchial NO levels. Multivariate analysis confirmed azithromycin use as a significant predictor of reduced bronchial NO (p = 0.038). This may be due to the drug downregulating the enzymes (NOS2) responsible for NO production as part of its anti-inflammatory action.

Bronchial (A) and nasal (B) NO levels categorized by therapy group (None, Antibiotics (AB), and AB + Azithromycin).

Pathogen Independence and Lung Function

Surprisingly, the specific type of bacteria present (e.g., Staphylococcus aureus vs. Pseudomonas aeruginosa) did not correlate with NO levels. Furthermore, no significant correlation was found between NO levels and FEV1 % predicted, indicating that NO serves as a marker of defense and inflammation rather than a direct proxy for current lung capacity.

Discussion and Future Directions

The reduction in nasal NO during systemic inflammation suggests a compromised "sinonasal gatekeeper," which may facilitate chronic lung infections. As a cross-sectional study, this research shows association rather than causality. Future longitudinal studies are needed to determine if dropping nasal NO levels can predict pulmonary exacerbations, potentially serving as an early warning system for clinicians to intervene before lung function declines.

Summary updated

Abstract

Given that NO in the paranasal sinuses is part of the first-line defence mechanism against pathogens, our finding of reduced nasal NO in CF patients with elevated systemic inflammatory markers indicates impaired upper airway defence. This may facilitate further pathogen acquisition in the sinonasal area, with consequences for lung colonisation and the overall outcome in CF.
BibTeX
@inproceedings{michl2013reduced,
  author = {R. Michl and Julia Hentschel and Christiane Fischer and James F. Beck and Jochen G. Mainz},
  title = {{Reduced Nasal Nitric Oxide Production in Cystic Fibrosis Patients with Elevated Systemic Inflammation Markers}},
  booktitle = {PLoS},
  year = {2013},
  doi = {10.1371/journal.pone.0079141},
}
Figure